sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_224> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_224> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB06209> ;
    a rdf:Statement ;
    rdfs:label "\"* Active pathological bleeding ( 4.1 4.2 4.3 Prasugrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage  [see Warnings and Precautions ( 5.1 6.1 Prasugrel tablets is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. In TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Prasugrel tablets (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). In patients without such a history, the incidence of stroke was 0.9% (0.2% ICH) and 1.0% (0.3% ICH) with Prasugrel tablets and clopidogrel, respectively. Patients with a history of ischemic stroke within 3 months of screening and patients with a history of hemorrhagic stroke at any time were excluded from TRITON-TIMI 38. Patients who experience a stroke or TIA while on Prasugrel tablets generally should have therapy discontinued  [see Adverse Reactions ( 6.1 14 Prasugrel tablets is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to prasugrel or any component of the product  [see Adverse Reactions ( 6.2\"" ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:MedicalContraindication .
  <https://identifiers.org/drugbank:DB06209> bl:category bl:Drug .
}